A phase II trial assessed the efficacy of the addition of bevacizumab to neo-adjuvant chemotherapy in resectable, non-squamous NSCLC and found that no patients with KRAS mutation had pathological response to neo-adjuvant bevacizumab combined with chemotherapy, whereas 35% of patients with KRAS wt status showed a significant pathological response [114]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.